Articles From: Xcite Energy Limited: Results for the 3 Month Period Ended 31 March 2013 to Xerium Technologies Reports Increased Sales and Adjusted EBITDA


2013/5/20
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1018891&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Limited: Results for the 3 Month Period Ended 31 March 2013 investment picks
2013/5/31
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1022395&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Ltd -Cancellation of Rowan Rig Option investment picks
2013/5/9
Xebec Announces 2013 First Quarter Operating Results Canada NewsWire * EBITDA is a non-IFRS financial measure and the Company defines it as earnings from operations excluding financial charges, taxes, foreign exchange loss (gain) and amortization.
Sign-up for Xebec Announces 2013 First Quarter Operating Results investment picks
2013/4/1
Xebec Announces Net Income of $1.9 Million on 7% increased Revenues for Fiscal 2012 Canada NewsWire Xebec Fiscal 2012 Fourth Quarter and Year-end Financial Results MONTREAL , April 1, 2013 /CNW Telbec/ - Xebec Adsorption Inc. (TSX: XBC) ("Xebec"), a provider of biogas upgrading, natural gas, field gas and hydrogen purification solutions for the clean energy and crude-derived fuels displacement markets, announced today its 2012 fourth quarter operating results.
Sign-up for Xebec Announces Net Income of $1.9 Million on 7% increased Revenues for Fiscal 2012 investment picks
2013/3/25
Pfizer Inc. (NYSE: PFE) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved XELJANZ ® (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies.
Sign-up for XELJANZ® (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA) investment picks
2013/3/21
RICHMOND, Va., March 21, 2013 (GLOBE NEWSWIRE) -- Xenith Bankshares, Inc. (Nasdaq:XBKS) , parent company of Xenith Bank, a business-focused bank serving the Greater Washington D.C., Richmond, and Greater Hampton Roads, Virginia markets, today announced that two members of its board of directors will not stand for re-election, and that the board of directors has nominated a new candidate for election to the board of directors, at the company's upcoming annual meeting of shareholders scheduled for May 2, 2013.
Sign-up for Xenith Bankshares, Inc. Announces Retirement of Directors and New Nominee investment picks
2013/5/1
RICHMOND, Va., May 1, 2013 (GLOBE NEWSWIRE) -- Xenith Bankshares, Inc. (Nasdaq:XBKS) , parent company of Xenith Bank, a business-focused bank serving the Greater Washington, D.C., Richmond and Greater Hampton Roads, Virginia markets, today announced financial results for the quarter ended March 31, 2013.
Sign-up for Xenith Bankshares, Inc. Reports Year-Over-Year Balance Sheet and Profitability Growth in First Quarter 2013 investment picks
2013/6/10
CARLSBAD, Calif.
Sign-up for Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies investment picks
2013/6/7
XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to five new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.
Sign-up for XenoPort Announces New Employment Inducement Awards investment picks
2013/4/5
XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to eight new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.
Sign-up for XenoPort Announces New Employment Inducement Awards investment picks
2013/3/4
XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to three new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.
Sign-up for XenoPort Announces New Employment Inducement Awards investment picks
2013/2/4
XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to two new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.
Sign-up for XenoPort Announces New Employment Inducement Awards investment picks
2013/5/3
XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to two new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.
Sign-up for XenoPort Announces New Employment Inducement Awards investment picks
2013/3/18
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will present the following posters at the 65 th Annual Meeting of the American Academy of Neurology in San Diego, California: AP (arbaclofen placarbil) Spasticity An Ongoing Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects with Spasticity Due to Multiple Sclerosis Session Info: Poster Session P03: March 19, 2:00 pm - 6:30 pm PT Poster #: P03.267 The Burden of Multiple Sclerosis-Related Spasticity on Indirect Costs and Requirement for Non-Professional Care: Results of a Cross-Sectional Study in the USA Session Info: Poster Session P03: March 19, 2:00 pm - 6:30 pm PT Poster #: P03.217 Impact of Spasticity on Healthcare Resource Utilisation: Results of a Cross-Sectional Study in the USA Session
Sign-up for XenoPort Announces Presentations at the American Academy of Neurology Meeting investment picks
2013/5/17
XenoPort, Inc. (Nasdaq: XNPT) announced today that shipments of Horizant ® (gabapentin enacarbil) Extended-Release Tablets to its distributor in the United States have commenced.
Sign-up for XenoPort Provides Update on Availability of Horizant investment picks
2013/4/12
XenoPort, Inc. (Nasdaq: XNPT) reported today that GlaxoSmithKline (GSK), who holds commercialization rights to Horizant ® (gabapentin enacarbil) Extended-Release Tablets in the United States during a transition period ending on April 30, 2013, has experienced manufacturing delays that have resulted in a stockout of Horizant .
Sign-up for XenoPort Provides Update on Its Introduction of Horizant investment picks
2013/4/24
XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the first quarter ended March 31, 2013.
Sign-up for XenoPort Reports First Quarter Financial Results investment picks
2013/3/11
XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2012.
Sign-up for XenoPort Reports Fourth Quarter and Year-End 2012 Financial Results investment picks
2013/5/20
XenoPort, Inc. (Nasdaq: XNPT) announced today top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil (AP) for the treatment of patients with spasticity due to multiple sclerosis (MS). The trial was unsuccessful in demonstrating that AP provided statistically significant improvement relative to placebo in the co-primary endpoints of the study.
Sign-up for XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients investment picks
2013/3/1
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Cowen and Company 33rd Annual Health Care Conference.
Sign-up for XenoPort to Present at the Cowen and Company 33rd Annual Health Care Conference investment picks
2013/6/11
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Wells Fargo Securities Research & Economics 2013 Healthcare Conference.
Sign-up for XenoPort to Present at the Wells Fargo Securities Healthcare Conference investment picks
2013/2/19
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentations at the RBC and Citigroup 2013 Healthcare Conferences.
Sign-up for XenoPort to Present at Upcoming Healthcare Conferences investment picks
2013/4/17
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its first quarter financial results on April 24, 2013 at approximately 4:30 p.m. Eastern Time.
Sign-up for XenoPort to Release First Quarter Financial Results on April 24 investment picks
2013/3/4
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its fourth quarter financial results on March 11, 2013 at approximately 4:30 p.m. Eastern Time.
Sign-up for XenoPort to Release Fourth Quarter and Year-End Financial Results on March 11, 2013 investment picks
2013/4/12
Biopharmaceutical firm XenoPort Inc. (XNPT) said GlaxoSmithKline PLC (GSK, GSK.LN) has experienced manufacturing delays that resulted in stockout of Horizant, a restless-leg syndrome drug.
Sign-up for XenoPort: Manufacturing Delays Caused Stockout of Horizant investment picks
2013/3/27
Xerium Technologies, Inc. (NYSE:XRM) a leading global manufacturer of engineered textiles and roll covers and provider of mechanical services used in the production of paper, paperboard, building products, nonwoven materials, and general industry, today announced a 350 ton global press felt production increase through a combination of the following actions: Xerium is increasing its capacity in its press felt plants in response to strong global demand from customers for Xerium’s high-end surface sensitive press felts.
Sign-up for Xerium Announces 350 Ton Press Felt Production Expansion investment picks
2013/4/19
Harold Bevis, Xerium CEO and President, announced today the restructuring of our European Executive and Global Technical Leadership functions.
Sign-up for Xerium Announces Organizational Realignment investment picks
2013/5/7
Xerium Technologies, Inc. (NYSE:XRM) a leading global provider of industrial consumable products and services, confirmed today that final results for the first quarter of 2013 match the previously issued preliminary results for the quarter.
Sign-up for Xerium Technologies Reports First Quarter 2013 Results Confirming Preliminary Results Release investment picks
2013/4/9
Xerium Technologies, Inc. (NYSE:XRM) a leading global provider of industrial consumables and mechanical services used in the production of paper, paperboard, building products and nonwoven materials, today announced certain preliminary financial results for the quarter ended March 31, 2013.
Sign-up for Xerium Technologies Reports Increased Sales and Adjusted EBITDA investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Xcite Energy Limited: Results for the 3 Month Period Ended 31 March 2013 to Xerium Technologies Reports Increased Sales and Adjusted EBITDA
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity